Willis Johnson & Associates’s Akebia Therapeutics AKBA Stock Holding History

Willis Johnson & Associates’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,500	Closed	-$28.2K	–	198
2025 Q4	$28.2K	Hold	17,500	–	–	﹤0.01%	185
2025 Q3	$47.8K	Hold	17,500	–	–	﹤0.01%	188
2025 Q2	$63.7K	Hold	17,500	–	–	﹤0.01%	165
2025 Q1	$33.6K	Hold	17,500	–	–	﹤0.01%	168
2024 Q4	$33.3K	Hold	17,500	–	–	﹤0.01%	155
2024 Q3	$23.1K	Hold	17,500	–	–	﹤0.01%	169
2024 Q2	$17.9K	Hold	17,500	–	–	﹤0.01%	155
2024 Q1	$32K	Hold	17,500	–	–	﹤0.01%	159
2023 Q4	$21.7K	Hold	17,500	–	–	﹤0.01%	141
2023 Q3	$19.9K	Buy	+17,500	New	+$22.5K	﹤0.01%	127

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Willis Johnson & Associates's AKBA Position: Q1 2026 in Review

Willis Johnson & Associates sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 17,500 shares — an estimated $28.2K sold.

Willis Johnson & Associates first reported a position in AKBA in Q3 2023 and held it in 10 quarters. The position peaked at $63.7K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Willis Johnson & Associates reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
Willis Johnson & Associates sold 17,500 Akebia Therapeutics shares in Q1 2026, an estimated $28.2K.
Willis Johnson & Associates first reported a position in Akebia Therapeutics in Q3 2023 and held it in 10 quarters.
Willis Johnson & Associates's Akebia Therapeutics position peaked at $63.7K in Q2 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Willis Johnson & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.